Empagliflozin for heart defects, congenital

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 15 Feb 2024: Trial registered, NCT06260059
  2. 17 Sep 2024: Trial started, NCT06260059

The trials

NCT05580510: " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "

State
State not given
Phase
Phase 2 and Phase 3
People
160 planned
Started
6 Feb 2023
Primary completion
28 Jul 2023
Arms
Conventional treatment plus Empagliflozin and Sacubitril/valsartan, Conventional treatment plus Empagliflozin
Results
None posted
Papers
doi:10.1002/ejhf.1342, doi:10.1056/nejmoa2022190, doi:10.1093/eurheartj/ehaa1012, doi:10.1161/circulationaha.120.052186, doi:10.1161/circulationaha.121.053659
  1. 14 Oct 2022: Trial registered

NCT06260059: Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease

State
Under way
Phase
Phase 4
People
40 planned
Started
17 Sep 2024
Primary completion
31 Dec 2026
Arms
Empagliflozin 10 MG
Results
None posted
  1. 15 Feb 2024: Trial registered
  2. 17 Sep 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Empagliflozin 10 MG, Empagliflozin 10 MG OD, Empagliflozin 25 MG, Empagliflozin10Mg Tab, Glyxambi component empagliflozin, Jardiance, Trijardy xr component empagliflozin.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.